Pharmacyte Biotech Inc (OTCMKTS:PMCB) is preparing to grab the headlines as it brought into light a 10-year old study pointing that the company’s Cell-in-a-Box had successfully showed complete remission of tumor in animals that received the therapy on 2-6 days of an earlier published preclinical study. The study was conducted using a colon cancer model aimed at treating malignant ascites.
10-year old findings
The malignant ascites is a fluid, which is found in abdominal cancers such as colon, ovarian, pancreatic and liver cancer. The fluid accumulates in the stomach and is a cause for pain and swelling of the abdomen. Pharmacyte Biotech Inc (OTCMKTS:PMCB)’s corporate video featured Dr. Matthias Lohr, a gastroenterologist, and oncologist, who established the fact that the company’s unique therapy had virtually cured the tumor in their study. The company also cited reasons as to why it failed to continue the study following the revelations of such astonishing facts.
At present, Pharmacyte Biotech Inc (OTCMKTS:PMCB) is involved into preclinical studies with Translational Drug Development (TD2) based in Scottsdale, Arizona. The objective behind the study is to explore the effectiveness of the company’s treatment against malignant ascites. The study is headed by Dr. Lohr, who is also Chairman of the company’s Scientific Advisory Board. In the TD2 study, Pharmacyte Biotech Inc (OTCMKTS:PMCB) is essentially working on ovarian cancer model and is trying to identify and develop parameters that will help its way into clinical trials.
The company’s CEO Kenneth L. Waggoner commented that their therapy has shown promising results, which has encouraged them to pursue clinical trial opportunities. He added that though the preclinical study was over a decade old, but its findings are quite significant for the company. Waggoner highlighted that the company’s Cell-in-a-box technology is much more developed now than ten years back. The stock of Pharmacyte Biotech Inc (OTCMKTS:PMCB) remained unchanged at $0.149 during the last session as 2.33 million shares changed hands.